562 related articles for article (PubMed ID: 28472989)
1. Circulating mutational portrait of cancer: manifestation of aggressive clonal events in both early and late stages.
Yang M; Topaloglu U; Petty WJ; Pagni M; Foley KL; Grant SC; Robinson M; Bitting RL; Thomas A; Alistar AT; Desnoyers RJ; Goodman M; Albright C; Porosnicu M; Vatca M; Qasem SA; DeYoung B; Kytola V; Nykter M; Chen K; Levine EA; Staren ED; D'Agostino RB; Petro RM; Blackstock W; Powell BL; Abraham E; Pasche B; Zhang W
J Hematol Oncol; 2017 May; 10(1):100. PubMed ID: 28472989
[TBL] [Abstract][Full Text] [Related]
2. A comparative study on ctDNA and tumor DNA mutations in lung cancer and benign cases with a high number of CTCs and CTECs.
Xie J; Hu B; Gong Y; He S; Lin J; Huang Q; Cheng J
J Transl Med; 2023 Dec; 21(1):873. PubMed ID: 38041139
[TBL] [Abstract][Full Text] [Related]
3. Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay.
Schwaederle M; Husain H; Fanta PT; Piccioni DE; Kesari S; Schwab RB; Banks KC; Lanman RB; Talasaz A; Parker BA; Kurzrock R
Oncotarget; 2016 Mar; 7(9):9707-17. PubMed ID: 26848768
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive genomic landscape and precision therapeutic approach in biliary tract cancers.
Okamura R; Kurzrock R; Mallory RJ; Fanta PT; Burgoyne AM; Clary BM; Kato S; Sicklick JK
Int J Cancer; 2021 Feb; 148(3):702-712. PubMed ID: 32700810
[TBL] [Abstract][Full Text] [Related]
5. Concurrent Tissue and Circulating Tumor DNA Molecular Profiling to Detect Guideline-Based Targeted Mutations in a Multicancer Cohort.
Iams WT; Mackay M; Ben-Shachar R; Drews J; Manghnani K; Hockenberry AJ; Cristofanilli M; Nimeiri H; Guinney J; Benson AB
JAMA Netw Open; 2024 Jan; 7(1):e2351700. PubMed ID: 38252441
[TBL] [Abstract][Full Text] [Related]
6. Patient specific circulating tumor DNA fingerprints to monitor treatment response across multiple tumors.
Li J; Jiang W; Wei J; Zhang J; Cai L; Luo M; Wang Z; Sun W; Wang S; Wang C; Dai C; Liu J; Wang G; Wang J; Xu Q; Deng Y
J Transl Med; 2020 Aug; 18(1):293. PubMed ID: 32738923
[TBL] [Abstract][Full Text] [Related]
7. Clinical application of circulating tumor DNA in metastatic cancers.
Raei N; Safaralizadeh R; Latifi-Navid S
Expert Rev Mol Diagn; 2023; 23(12):1209-1220. PubMed ID: 37797209
[TBL] [Abstract][Full Text] [Related]
8. The characteristics of ctDNA reveal the high complexity in matching the corresponding tumor tissues.
Yang N; Li Y; Liu Z; Qin H; Du D; Cao X; Cao X; Li J; Li D; Jiang B; Duan L; Yang H; Zhang Z; Lin H; Li J; Yang Z; Xiong L; Shen H; Lin L; Li F
BMC Cancer; 2018 Mar; 18(1):319. PubMed ID: 29566644
[TBL] [Abstract][Full Text] [Related]
9. Circulating tumor DNA detectable in early- and late-stage colorectal cancer patients.
Yang YC; Wang D; Jin L; Yao HW; Zhang JH; Wang J; Zhao XM; Shen CY; Chen W; Wang XL; Shi R; Chen SY; Zhang ZT
Biosci Rep; 2018 Aug; 38(4):. PubMed ID: 29914973
[TBL] [Abstract][Full Text] [Related]
10. Tumor-derived DNA from pleural effusion supernatant as a promising alternative to tumor tissue in genomic profiling of advanced lung cancer.
Tong L; Ding N; Tong X; Li J; Zhang Y; Wang X; Xu X; Ye M; Li C; Wu X; Bao H; Zhang X; Hong Q; Song Y; Shao YW; Bai C; Zhou J; Hu J
Theranostics; 2019; 9(19):5532-5541. PubMed ID: 31534501
[TBL] [Abstract][Full Text] [Related]
11. Hybrid Capture-based Genomic Profiling of Circulating Tumor DNA From Patients With Advanced Ovarian
Shen W; Shan B; Liang S; Zhang J; Yu Y; Zhang Y; Wang G; Bai Y; Qian B; Lu J; Jiang Z
Pathol Oncol Res; 2021; 27():581534. PubMed ID: 34257528
[No Abstract] [Full Text] [Related]
12. Exploring the tumor genomic landscape of aggressive prostate cancer by whole-genome sequencing of tissue or liquid biopsies.
Weiss S; Lamy P; Rusan M; Nørgaard M; Ulhøi BP; Knudsen M; Kassentoft CG; Farajzadeh L; Jensen JB; Pedersen JS; Borre M; Sørensen KD
Int J Cancer; 2024 Jul; 155(2):298-313. PubMed ID: 38602058
[TBL] [Abstract][Full Text] [Related]
13. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution.
Abbosh C; Birkbak NJ; Wilson GA; Jamal-Hanjani M; Constantin T; Salari R; Le Quesne J; Moore DA; Veeriah S; Rosenthal R; Marafioti T; Kirkizlar E; Watkins TBK; McGranahan N; Ward S; Martinson L; Riley J; Fraioli F; Al Bakir M; Grönroos E; Zambrana F; Endozo R; Bi WL; Fennessy FM; Sponer N; Johnson D; Laycock J; Shafi S; Czyzewska-Khan J; Rowan A; Chambers T; Matthews N; Turajlic S; Hiley C; Lee SM; Forster MD; Ahmad T; Falzon M; Borg E; Lawrence D; Hayward M; Kolvekar S; Panagiotopoulos N; Janes SM; Thakrar R; Ahmed A; Blackhall F; Summers Y; Hafez D; Naik A; Ganguly A; Kareht S; Shah R; Joseph L; Marie Quinn A; Crosbie PA; Naidu B; Middleton G; Langman G; Trotter S; Nicolson M; Remmen H; Kerr K; Chetty M; Gomersall L; Fennell DA; Nakas A; Rathinam S; Anand G; Khan S; Russell P; Ezhil V; Ismail B; Irvin-Sellers M; Prakash V; Lester JF; Kornaszewska M; Attanoos R; Adams H; Davies H; Oukrif D; Akarca AU; Hartley JA; Lowe HL; Lock S; Iles N; Bell H; Ngai Y; Elgar G; Szallasi Z; Schwarz RF; Herrero J; Stewart A; Quezada SA; Peggs KS; Van Loo P; Dive C; Lin CJ; Rabinowitz M; Aerts HJWL; Hackshaw A; Shaw JA; Zimmermann BG; ; ; Swanton C
Nature; 2017 Apr; 545(7655):446-451. PubMed ID: 28445469
[TBL] [Abstract][Full Text] [Related]
14. Mutated circulating tumor DNA as a liquid biopsy in lung cancer detection and treatment.
Filipska M; Rosell R
Mol Oncol; 2021 Jun; 15(6):1667-1682. PubMed ID: 33969622
[TBL] [Abstract][Full Text] [Related]
15. Liquid Biopsy to Identify Actionable Genomic Alterations.
Ou SI; Nagasaka M; Zhu VW
Am Soc Clin Oncol Educ Book; 2018 May; 38():978-997. PubMed ID: 30231331
[TBL] [Abstract][Full Text] [Related]
16. Detection of circulating tumor cells and circulating tumor DNA before and after mammographic breast compression in a cohort of breast cancer patients scheduled for neoadjuvant treatment.
Förnvik D; Aaltonen KE; Chen Y; George AM; Brueffer C; Rigo R; Loman N; Saal LH; Rydén L
Breast Cancer Res Treat; 2019 Sep; 177(2):447-455. PubMed ID: 31236809
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of Commercial Circulating Tumor DNA Test in Metastatic Prostate Cancer.
Taavitsainen S; Annala M; Ledet E; Beja K; Miller PJ; Moses M; Nykter M; Chi KN; Sartor O; Wyatt AW
JCO Precis Oncol; 2019; 3():. PubMed ID: 32914020
[TBL] [Abstract][Full Text] [Related]
18. Plasma ctDNA enhances the tissue-based detection of oncodriver mutations in colorectal cancer.
Wang W; Huang Y; Kong J; Lu L; Liao Q; Zhu J; Wang T; Yan L; Dai M; Chen Z; You J
Clin Transl Oncol; 2024 May; ():. PubMed ID: 38777950
[TBL] [Abstract][Full Text] [Related]
19. Non-invasive detection of genome-wide somatic copy number alterations by liquid biopsies.
Heitzer E; Ulz P; Geigl JB; Speicher MR
Mol Oncol; 2016 Mar; 10(3):494-502. PubMed ID: 26778171
[TBL] [Abstract][Full Text] [Related]
20. Serial Profiling of Circulating Tumor DNA Identifies Dynamic Evolution of Clinically Actionable Genomic Alterations in High-Risk Neuroblastoma.
Bosse KR; Giudice AM; Lane MV; McIntyre B; Schürch PM; Pascual-Pasto G; Buongervino SN; Suresh S; Fitzsimmons A; Hyman A; Gemino-Borromeo M; Saggio J; Berko ER; Daniels AA; Stundon J; Friedrichsen M; Liu X; Margolis ML; Li MM; Tierno MB; Oxnard GR; Maris JM; Mossé YP
Cancer Discov; 2022 Dec; 12(12):2800-2819. PubMed ID: 36108156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
